A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Public ClinicalTrials.gov record NCT02207244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).
Study identification
- NCT ID
- NCT02207244
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 992 participants
Conditions and interventions
Conditions
Interventions
- Guselkumab 100 mg Drug
- Placebo for guselkumab Drug
- Adalimumab Drug
- Placebo for adalimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2014 (Actual)
- Primary completion
- Oct 1, 2015 (Actual)
- Completion
- Jul 1, 2020 (Actual)
- Last update posted
- Jul 22, 2021
2014 – 2020
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Bakersfield | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Coral Gables | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Newnan | Georgia | — | — |
| Not listed | Sandy Springs | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Rolling Meadows | Illinois | — | — |
| Not listed | Skokie | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Plainfield | Indiana | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Andover | Massachusetts | — | — |
| Not listed | Fort Gratiot | Michigan | — | — |
| Not listed | Troy | Michigan | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Gahanna | Ohio | — | — |
| Not listed | Norman | Oklahoma | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Johnston | Rhode Island | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02207244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2021 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02207244 live on ClinicalTrials.gov.